Yingcai Feng

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

Hong Yuan, Yingcai Feng, Hanzi Sun et al. · FEBS Open Bio · 2021 · 70 citations · Full text

Immunology, Cc′ Loop, Molecular Biology +16

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in <i>BRAF</i> -Mutated Colorectal Cancers

Zhiyu Tang, Xi Yuan, Rong Du et al. · Molecular Cancer Therapeutics · 2015 · 69 citations · Full text

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

Hexiang Wang, Bo Ren, Ye Liu et al. · Journal of Medicinal Chemistry · 2020 · 69 citations · Full text

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Jiuyang Liu, Shuran Li, Qin Wang et al. · Blood · 2024 · 61 citations · Full text

Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab

Yingcai Feng, Yuan Hong, Hanzi Sun et al. · Cancer Research · 2019 · 16 citations

Investigational Anti-pd-1 Antibody, Ligand Pd-l1/l2, Immunology +19